Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Shares Issued (2017 - 2025)

Historic Shares Issued for Spyre Therapeutics (SYRE) over the last 9 years, with Q3 2025 value amounting to $491000.0.

  • Spyre Therapeutics' Shares Issued rose 32318.18% to $491000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$159.8 million, marking a year-over-year decrease of 19447.18%. This contributed to the annual value of $7.5 million for FY2024, which is 175456.79% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Shares Issued of $491000.0 as of Q3 2025, which was up 32318.18% from $731000.0 recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Shares Issued registered a high of $169.2 million during Q1 2024, and its lowest value of -$161.3 million during Q4 2024.
  • For the 5-year period, Spyre Therapeutics' Shares Issued averaged around $724875.0, with its median value being $216500.0 (2021).
  • Examining YoY changes over the last 5 years, Spyre Therapeutics' Shares Issued showed a top increase of 93992777.78% in 2024 and a maximum decrease of 5731241.13% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Shares Issued (Quarter) stood at $249000.0 in 2021, then crashed by 84.74% to $38000.0 in 2022, then soared by 642.11% to $282000.0 in 2023, then crashed by 57312.41% to -$161.3 million in 2024, then skyrocketed by 100.3% to $491000.0 in 2025.
  • Its last three reported values are $491000.0 in Q3 2025, $731000.0 for Q2 2025, and $335000.0 during Q1 2025.